{"DataElement":{"publicId":"6042209","version":"1","preferredName":"Stereotactic Body Radiation Therapy Other Liver Hepatocellular Cancer Gross Tumor Volume Number Text","preferredDefinition":"Text that describes another liver gross hepatocellular tumor volume site number not already specified.","longName":"SBRT_OT_LV_ST_TXT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"6041962","version":"1","preferredName":"Stereotactic Body Radiation Therapy Hepatocellular Carcinoma Other Gross Tumor Volume","preferredDefinition":"Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine._A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation._Different than the one(s) previously specified or mentioned._Visible to the naked eye._The size of a cancer measured by the amount of space taken up by the tumor. For example, the tumor volume of prostate cancer is the percentage of the prostate taken up by the tumor.","longName":"6028394v1.0:6041960v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"6028394","version":"1","preferredName":"Stereotactic Body Radiation Therapy","preferredDefinition":"Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.","longName":"C118286","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stereotactic Body Radiation Therapy","conceptCode":"C118286","definition":"Stereotactic radiation therapy in which one or several maximum dose radiation treatments are delivered targeting cancers of the body, excluding the brain or spine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5E08F3C8-D17E-64FA-E053-F662850A58F1","latestVersionIndicator":"Yes","beginDate":"2017-11-15","endDate":null,"createdBy":"SOKKERL","dateCreated":"2017-11-15","modifiedBy":"ONEDATA","dateModified":"2017-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6041960","version":"1","preferredName":"Hepatocellular Carcinoma Other Gross Tumor Volume","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.:Different than the one(s) previously specified or mentioned.:Visible to the naked eye.:The size of a cancer measured by the amount of space taken up by the tumor. For example, the tumor volume of prostate cancer is the percentage of the prostate taken up by the tumor.","longName":"C3099:C17649:C43566:C94515","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"3"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gross","conceptCode":"C43566","definition":"Visible to the naked eye.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Volume","conceptCode":"C94515","definition":"The volume of tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"601842F6-4E8A-6261-E053-F662850A0B54","latestVersionIndicator":"Yes","beginDate":"2017-12-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-12","modifiedBy":"ONEDATA","dateModified":"2017-12-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"601842F6-4E9B-6261-E053-F662850A0B54","latestVersionIndicator":"Yes","beginDate":"2017-12-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-12","modifiedBy":"COOPERM","dateModified":"2017-12-15","changeDescription":"Created for Auditi request 11.14.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2857322","version":"1","preferredName":"Other Specify Text","preferredDefinition":"The free text field that describes another response when other is chosen from a list of values.","longName":"OTHR_SPEC_TXT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2857047","version":"1","preferredName":"Other Specify Text","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.:Text; the words of something written.","longName":"C17649:C25685:C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"660AABE0-46ED-4890-E040-BB89AD431D5B","latestVersionIndicator":"Yes","beginDate":"2009-03-26","endDate":null,"createdBy":"SCOTTLO","dateCreated":"2009-03-26","modifiedBy":"ONEDATA","dateModified":"2009-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"6648A78E-AB33-047A-E040-BB89AD4324AB","latestVersionIndicator":"Yes","beginDate":"2009-03-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-03-29","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/22/17 tt transferred context, added registration status and CSI per Round 5 finalization task. Modified for The Cancer Genome Atlas (TCGA) by request of T. Lichtenberg (JP) 12/2010.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Other, Specify","type":"Preferred Question Text","description":"Other, Specify","url":null,"context":"NCIP"}],"origin":"Princess Margaret Cancer Centre, Toronto, ON","workflowStatus":"RELEASED","registrationStatus":"Application","id":"602D6A5F-0CB5-46A9-E053-F662850A0387","latestVersionIndicator":"Yes","beginDate":"2017-12-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-12","modifiedBy":"COOPERM","dateModified":"2017-12-15","changeDescription":"Created for Auditi SBRT request 11.14.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}